Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jirovecii pneumonia over the course of the AIDS epidemic.

@article{Morris2008IsTA,
  title={Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jirovecii pneumonia over the course of the AIDS epidemic.},
  author={Alison Morris},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2008},
  volume={46 4},
  pages={
          634-6
        }
}
  • A. Morris
  • Published 15 February 2008
  • Medicine, Biology
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The epidemiological characteristics and outcome of HIV-associated Pneumocystis jirovedi pneumonia (PCP) have shifted multiple times over the course of the AIDS epidemic. Despite the availability of HAART, PCP remains a leading cause of morbidity and mortality. The article by Walzer et al. [1] in this issue of Clinical Infectious Diseases summarizes the experience with HIV-associated PCP over a 21- 
View on PubMed
antimicrobe.org
24 Citations
Background Citations
9
Results Citations
1

24 Citations

Citation Type

Citation Type

Current understanding of Pneumocystis immunology.
TLDR
This article focuses on research conducted during the previous 5 years regarding the host immune response to Pneumocystis, including innate, cell-mediated and humoral immunity, and associated immunotherapies tested against PCP.
Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals.
Pneumocystis infection and the pathogenesis of chronic obstructive pulmonary disease
TLDR
It is shown that antibody response to the Pc protein, kexin (KEX1), correlates with protection from colonization, Pc pneumonia, and COPD, and support the hypothesis that immunity to KEX1 may be critical to controlling Pc colonization and preventing or slowing development of COPD.
Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients
TLDR
Clinical presentation of PCP only rarely presented with fulminant respiratory symptoms requiring ICU admission, with similar results and outcomes for HIV patients and RTRs.
Improved outcome of Pneumocystis pneumonia by early treatment.
Clinical and radiographic peculiarities of changes in lungs at pneumocystosis in patients with aids
TLDR
Radiography of thorax stays is the main objective method of diagnostics of changes in lungs in patients with AIDS and peculiarities of radiographic manifestations of the modern course of pneumocystic pneumonia from an initial changes of lung pattern to an apparent picture are ascertained.
Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians.
Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection
TLDR
It is shown that therapeutic and prophylactic treatment ofPCP with echinocandins, compounds which inhibit the synthesis of β -1,3-D-glucan, depleted cysts in rodent models of PCP, while sparing the trophic forms which remained in significant numbers, provide novel and powerful chemical tools to probe the still poorly understood bi-phasic life cycle of this genus of fungal pathogens.
Ploidy of Cell-Sorted Trophic and Cystic Forms of Pneumocystis carinii
TLDR
Ploidy data of P. carinii life cycle stages shed new light on the complexity of its modes of proliferation, an unusual finding that could be related to asymmetrical mitotic divisions occurring in other fungal species to create genetic diversity at lower energetic expenses than mating.
Incidencia de neumonía por Pneumocystis jirovecii en pacientes con síndrome de inmunodeficiencia adquirida en el Hospital La María de Medellín (Colombia), entre 2008-2009
...
1
2
3
...

References

SHOWING 1-10 OF 11 REFERENCES
Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.
TLDR
Mortality risk factors for PCP were identifiable at or soon after hospitalization and the trend towards improved outcome after June 1996 occurred in the absence of highly active antiretroviral therapy.
Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003.
  • E. Teshale, D. Hanson, +4 authors P. Sullivan
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
Despite widespread availability of effective prophylaxis, Pneumocystis jiroveci (formerly carinii) pneumonia (PCP) continues to cause substantial morbidity among HIV-infected persons [ 14]. The US…
Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy
TLDR
Observed improved outcomes from severe PCP for patients admitted to the ICU occurred in the absence of intervention with HAART and probably reflect general improvements in ICU management of respiratory failure and ARDS rather than improvements in the management of PCP.
Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia
TLDR
Use of HAART is an independent predictor of decreased mortality in severe PCP and may represent a potential therapy to improve outcome in this disease.
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for european patients with acquired immunodeficiency syndrome
TLDR
Increased awareness of early symptoms of P carinii pneumonia and better treatment of the pneumonia may have led to improvement in short-term survival over time, whereas the introduction of zidovudine and increased use of secondary P car inii pneumonia prophylaxis may have resulted in the recent increase in survival 1 and 2 years after the diagnosis.
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Multicentre Study Group on AIDS in Europe.
TLDR
Increased awareness of early symptoms of P carinii pneumonia and better treatment of the pneumonia may have led to improvement in short-term survival over time, whereas the introduction of zidovudine and increased use of secondary P car inii pneumonia prophylaxis may have resulted in the recent increase in survival 1 and 2 years after the diagnosis.
Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.
TLDR
Survival rates for first, second, and third episodes of PCP in patients with the acquired immunodeficiency syndrome are not different and treatment for second andThird episodes of acute PCP may be as successful as in initial episodes.
A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era.
TLDR
A new staging system for predicting inpatient mortality for patients with HIV-associated PCP admitted between 1995 and 1997 is developed and may be useful for severity of illness adjustment in the current era while exploring current variation in HIV- associated PCP in patient mortality rates among hospitals and across cities.
improving survival of AIDS patients St Mary's Hospital, London, 1982-1991 Hospital service interventions and
TLDR
Subsequent medical follow up combined with PCP prophylaxis and zidovudine were significantly associated with long-term survival, and early diagnosis of HIV-1 infection with early diagnosis and treatment of first episode of PCP was associated with improved episode survival.
US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era.
TLDR
Quality of care for patients with PCP improved, but further efforts are needed to facilitate the appropriate management of CAP, and variations in processes of care and lengths of in-hospital stays, but not mortality rates, were noted at VA, public, private not-for-profits hospitals, and for-profit hospitals.
...
1
2
...